Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Cartesian Therapeutics (RNAC) over the last 10 years, with Q3 2025 value amounting to 0.25%.

  • Cartesian Therapeutics' Return on Capital Employed fell 1100.0% to 0.25% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.25%, marking a year-over-year decrease of 1100.0%. This contributed to the annual value of 0.13% for FY2024, which is 3900.0% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Return on Capital Employed of 0.25% as of Q3 2025, which was down 1100.0% from 0.23% recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Return on Capital Employed peaked at 0.2% during Q2 2022, and registered a low of 0.63% during Q4 2023.
  • Its 5-year average for Return on Capital Employed is 0.18%, with a median of 0.16% in 2024.
  • Per our database at Business Quant, Cartesian Therapeutics' Return on Capital Employed skyrocketed by 9900bps in 2021 and then crashed by -7400bps in 2023.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Return on Capital Employed stood at 0.05% in 2021, then soared by 296bps to 0.1% in 2022, then tumbled by -736bps to 0.63% in 2023, then skyrocketed by 83bps to 0.1% in 2024, then crashed by -140bps to 0.25% in 2025.
  • Its Return on Capital Employed stands at 0.25% for Q3 2025, versus 0.23% for Q2 2025 and 0.13% for Q1 2025.